INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION
QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS
QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with the use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS
Dose modifications are recommended when using the following:

Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors

Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS
Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

Please see full Prescribing Information.

Reference: 1. Data on file. AbbVie Inc.

© 2024 AbbVie. All rights reserved.
All trademarks are the property of their respective owners.

US-QLP-240176  09/24